Literature DB >> 23639312

Tumor suppressors status in cancer cell line Encyclopedia.

Dmitriy Sonkin1, Mehedi Hassan, Denis J Murphy, Tatiana V Tatarinova.   

Abstract

Tumor suppressors play a major role in the etiology of human cancer, and typically achieve a tumor-promoting effect upon complete functional inactivation. Bi-allelic inactivation of tumor suppressors may occur through genetic mechanisms (such as loss of function mutation, copy number (CN) loss, or loss of heterozygosity (LOH)), epigenetic mechanisms (such as promoter methylation or histone modification), or a combination of the two. We report systematically derived status of 69 known or putative tumor suppressors, across 799 samples of the Cancer Cell Line Encyclopedia. In order to generate such resource we constructed a novel comprehensive computational framework for the assessment of tumor suppressor functional "status". This approach utilizes several orthogonal genomic data types, including mutation data, copy number, LOH and expression. Through correlation with additional data types (compound sensitivity and gene set activity) we show that this integrative method provides a more accurate assessment of tumor suppressor status than can be inferred by expression, copy number, or mutation alone. This approach has the potential for a more realistic assessment of tumor suppressor genes for both basic and translational oncology research.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CCLE; Cancer cell line; DNA methylation; Epigenetics; Loss of function; Tumor suppressor

Mesh:

Year:  2013        PMID: 23639312      PMCID: PMC3729735          DOI: 10.1016/j.molonc.2013.04.001

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  27 in total

Review 1.  Human tumor suppressor genes.

Authors:  E J Stanbridge
Journal:  Annu Rev Genet       Date:  1990       Impact factor: 16.830

2.  Genome-wide in situ exon capture for selective resequencing.

Authors:  Emily Hodges; Zhenyu Xuan; Vivekanand Balija; Melissa Kramer; Michael N Molla; Steven W Smith; Christina M Middle; Matthew J Rodesch; Thomas J Albert; Gregory J Hannon; W Richard McCombie
Journal:  Nat Genet       Date:  2007-11-04       Impact factor: 38.330

Review 3.  X-chromosome inactivation in mammals.

Authors:  E Heard; P Clerc; P Avner
Journal:  Annu Rev Genet       Date:  1997       Impact factor: 16.830

Review 4.  The fundamental role of epigenetic events in cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Nat Rev Genet       Date:  2002-06       Impact factor: 53.242

5.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.

Authors:  Audrey Petitjean; Ewy Mathe; Shunsuke Kato; Chikashi Ishioka; Sean V Tavtigian; Pierre Hainaut; Magali Olivier
Journal:  Hum Mutat       Date:  2007-06       Impact factor: 4.878

Review 6.  Tumor suppressors and cell metabolism: a recipe for cancer growth.

Authors:  Russell G Jones; Craig B Thompson
Journal:  Genes Dev       Date:  2009-03-01       Impact factor: 11.361

7.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

8.  KEGG for integration and interpretation of large-scale molecular data sets.

Authors:  Minoru Kanehisa; Susumu Goto; Yoko Sato; Miho Furumichi; Mao Tanabe
Journal:  Nucleic Acids Res       Date:  2011-11-10       Impact factor: 16.971

9.  The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Authors:  Jordi Barretina; Giordano Caponigro; Nicolas Stransky; Kavitha Venkatesan; Adam A Margolin; Sungjoon Kim; Christopher J Wilson; Joseph Lehár; Gregory V Kryukov; Dmitriy Sonkin; Anupama Reddy; Manway Liu; Lauren Murray; Michael F Berger; John E Monahan; Paula Morais; Jodi Meltzer; Adam Korejwa; Judit Jané-Valbuena; Felipa A Mapa; Joseph Thibault; Eva Bric-Furlong; Pichai Raman; Aaron Shipway; Ingo H Engels; Jill Cheng; Guoying K Yu; Jianjun Yu; Peter Aspesi; Melanie de Silva; Kalpana Jagtap; Michael D Jones; Li Wang; Charles Hatton; Emanuele Palescandolo; Supriya Gupta; Scott Mahan; Carrie Sougnez; Robert C Onofrio; Ted Liefeld; Laura MacConaill; Wendy Winckler; Michael Reich; Nanxin Li; Jill P Mesirov; Stacey B Gabriel; Gad Getz; Kristin Ardlie; Vivien Chan; Vic E Myer; Barbara L Weber; Jeff Porter; Markus Warmuth; Peter Finan; Jennifer L Harris; Matthew Meyerson; Todd R Golub; Michael P Morrissey; William R Sellers; Robert Schlegel; Levi A Garraway
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

10.  Signal transduction pathway profiling of individual tumor samples.

Authors:  Thomas Breslin; Morten Krogh; Carsten Peterson; Carl Troein
Journal:  BMC Bioinformatics       Date:  2005-06-29       Impact factor: 3.169

View more
  15 in total

1.  A Rapid and Sensitive Next-Generation Sequencing Method to Detect RB1 Mutations Improves Care for Retinoblastoma Patients and Their Families.

Authors:  Wenhui L Li; Jonathan Buckley; Pedro A Sanchez-Lara; Dennis T Maglinte; Lucy Viduetsky; Tatiana V Tatarinova; Jennifer G Aparicio; Jonathan W Kim; Margaret Au; Dejerianne Ostrow; Thomas C Lee; Maurice O'Gorman; Alexander Judkins; David Cobrinik; Timothy J Triche
Journal:  J Mol Diagn       Date:  2016-05-04       Impact factor: 5.568

2.  Tumor suppressors status in cancer cell line Encyclopedia.

Authors:  Dmitriy Sonkin; Mehedi Hassan; Denis J Murphy; Tatiana V Tatarinova
Journal:  Mol Oncol       Date:  2013-04-11       Impact factor: 6.603

3.  Cross-species analysis of genic GC3 content and DNA methylation patterns.

Authors:  Tatiana Tatarinova; Eran Elhaik; Matteo Pellegrini
Journal:  Genome Biol Evol       Date:  2013       Impact factor: 3.416

4.  Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity.

Authors:  Ana B Pavel; Dmitriy Sonkin; Anupama Reddy
Journal:  BMC Syst Biol       Date:  2016-02-11

5.  The kinase inhibitor D11 induces caspase-mediated cell death in cancer cells resistant to chemotherapeutic treatment.

Authors:  Barbara Guerra; Mette Fischer; Susanne Schaefer; Olaf-Georg Issinger
Journal:  J Exp Clin Cancer Res       Date:  2015-10-20

6.  Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.

Authors:  Mariia Patyka; Zeinab Sharifi; Kevin Petrecca; Jose Mansure; Bertrand Jean-Claude; Siham Sabri
Journal:  Oncotarget       Date:  2016-09-13

7.  Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations.

Authors:  Ram Ajore; David Raiser; Marie McConkey; Magnus Jöud; Bernd Boidol; Brenton Mar; Gordon Saksena; David M Weinstock; Scott Armstrong; Steven R Ellis; Benjamin L Ebert; Björn Nilsson
Journal:  EMBO Mol Med       Date:  2017-04       Impact factor: 12.137

8.  Systemic Analysis of the DNA Replication Regulator MCM Complex in Ovarian Cancer and Its Prognostic Value.

Authors:  Yukun Li; Juan Zou; Qunfeng Zhang; Feifei Quan; Lu Cao; Xiaodi Zhang; Jue Liu; Daichao Wu
Journal:  Front Oncol       Date:  2021-06-09       Impact factor: 6.244

Review 9.  Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine.

Authors:  Ekaterina A Kotelnikova; Mikhail Pyatnitskiy; Anna Paleeva; Olga Kremenetskaya; Dmitriy Vinogradov
Journal:  Oncotarget       Date:  2016-08-09

10.  Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy.

Authors:  Endang Nuryadi; Yasushi Sasaki; Yoshihiko Hagiwara; Tiara Bunga Mayang Permata; Hiro Sato; Shuichiro Komatsu; Yuya Yoshimoto; Kazutoshi Murata; Ken Ando; Nobuteru Kubo; Noriyuki Okonogi; Yosuke Takakusagi; Akiko Adachi; Mototaro Iwanaga; Keisuke Tsuchida; Tomoaki Tamaki; Shin-Ei Noda; Yuka Hirota; Atsushi Shibata; Tatsuya Ohno; Takashi Tokino; Takahiro Oike; Takashi Nakano
Journal:  Oncotarget       Date:  2018-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.